Resources
35 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 7/13/2020 (updated 9/2/2021)
The Facts About Buprenorphine for Treatment of Opioid Addiction is available in many languages, including Spanish.
Posted 12/31/2019 (updated 9/2/2021)
To provide a procedure that both Nursing and Correctional Staff can adhere to for the orderly and secure issuance of suboxone.
Posted 10/23/2020 (updated 9/2/2021)
This article offers data regarding offering buprenorphine treatment at a public hospital primary care setting using a home, unobserved induction protocol.
Posted 10/23/2020 (updated 9/2/2021)
The goal of this module is to train providers to initiate patients on buprenorphine safely and effectively.
Posted 10/23/2020 (updated 9/2/2021)
This report analyzes Medicaid State Drug Utilization Data from 2011 to 2018 to track Medicaid prescriptions, unit prices, and spending after accounting for federal rebates paid by manufactures to Medicaid programs for extended-release MOUDs.
Posted 10/23/2020 (updated 9/2/2021)
The objective of this report was to perform a systematic review of the beneficial and harmful effects of BUP-ER 100 mg and 300 mg for the management of moderate-to-severe OUD in adult patients who have been inducted and clinically stabilized on a transmucosal buprenorphine-containing product.
Posted 10/23/2020 (updated 9/2/2021)
These pilot study results suggest comparable safety and effectiveness of unobserved and office induction and point toward utilization of non-inferiority design during future definitive protocol development.
Posted 2/18/2021 (updated 9/2/2021)
Opioid use disorder (OUD), a chronic disease, is a major public health problem. Despite availability of effective treatment, too few people receive it and treatment retention is low. Understanding barriers and facilitators of treatment access and retention is needed to improve outcomes for people with OUD.
In this study we sought to assess 3-month outcomes from a patient-centered practice that included MAT with buprenorphine or naltrexone plus the option to participate in psychosocial treatments. The psychosocial treatments included case management, psychotherapy, peer recovery groups such as Narcotics Anonymous or Smart Recovery, or peer support through a local harm reduction program.
Posted 3/30/2021 (updated 9/2/2021)
This toolkit provides correctional administrators and health care providers the information necessary to plan and implement MAT programs within jails and prisons.
Posted 5/26/2021 (updated 9/2/2021)
Opioid dependence is a chronic relapsing disorder with considerable individual and global public health burden. The current standard of care for opioid dependence includes treatment with methadone or sublingual (SL) buprenorphine or buprenorphine-naloxone (hereafter, buprenorphine), combined with psychosocial and behavioral support. Both medications are associated with reductions in mortality, illicit opioid use, bloodborne viral infections, and criminal behavior as well as better cost-effectiveness than no treatment or psychosocial treatment alone. Buprenorphine is a partial μ-opioid receptor agonist, enabling office-based treatment for nonsupervised or take-home use of the medication. However, SL formulations of buprenorphine are prone to nonmedical use (eg, injecting, diversion), prompting models of care, particularly in the early phases of treatment, requiring regular attendance at clinics or pharmacies for administration of doses.